Physician profile
Mark A Bush
NPI 1730733783
$51,979.17
in general payments reported to CMS, 2019-2025
24 companies · $14K in 2025
The $14K reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,689 · 2022: $2,160 · 2023: $15K · 2024: $19K · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $42K · Food and Beverage: $5,054 · Travel and Lodging: $1,119 · Education: $19.67.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $41,937.50 |
| Food and Beverage | $5,054.47 |
| Travel and Lodging | $1,119.05 |
| Education | $19.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $45,367.14 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,075.78 | 2021-2024 | Caplyta |
| Neurocrine Biosciences, INC. | $1,039.11 | 2021-2025 | Ingrezza |
| Alkermes, INC. | $977.69 | 2021-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $809.61 | 2021-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Lundbeck LLC | $557.29 | 2021-2025 | Rexulti, Abilify Maintena |
| Otsuka America Pharmaceutical, INC. | $507.77 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Supernus Pharmaceuticals, INC. | $488.28 | 2024-2025 | Qelbree |
| Indivior INC. | $229.05 | 2021-2023 | Perseris |
| Teva Pharmaceuticals USA, INC. | $207.61 | 2022-2025 | Austedo Xr, Austedo, Austedo Xr |
| Sunovion Pharmaceuticals INC. | $155.66 | 2021-2022 | |
| Axsome Therapeutics, INC. | $154.10 | 2022-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $150.60 | 2024-2025 | Fanapt, Hetlioz |
| Glaxosmithkline, LLC. | $47.25 | 2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $36.17 | 2023 | Mounjaro |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $23.36 | 2025 | Jornay Pm |
| Novo Nordisk INC | $22.87 | 2022 | |
| Noven Pharmaceuticals, INC. | $21.43 | 2021 | |
| Exact Sciences Corporation | $20.83 | 2023 | Cologuard Collection Kit |
| Bausch Health US, LLC | $19.94 | 2025 | Aplenzin, Wellbutrin |
| Allergan, INC. | $17.66 | 2021 | |
| Amgen INC. | $17.27 | 2022 | |
| Insulet Corporation | $17.02 | 2023 | Omnipod |
| Noven Therapeutics, LLC | $15.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Bush listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.